• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

    11/27/24 7:01:59 PM ET
    $PSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTX alert in real time by email
    SC 13D/A 1 p24-3458sc13da.htm POSEIDA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13D
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 2)*
     

    Poseida Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)  
     
    73730P108
    (CUSIP Number)
     

    Matthew Halbower

    Pentwater Capital Management LP

    1001 10th Avenue South, Suite 216

    Naples, FL 34102

    239-384-9750

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
    November 25, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

    (Page 1 of 8 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“the Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 73730P108Schedule 13D/APage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Pentwater Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐
    (b) ☐
    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)

    OO

    5 Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) ☐
    6 Citizenship or place of organization Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7 SOLE VOTING POWER
    0  
    8 SHARED VOTING POWER
    8,625,000  
    9 SOLE DISPOSITIVE POWER
    0  
    10 SHARED DISPOSITIVE POWER
    8,625,000  
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,625,000  
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.8%
    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN, IA

                   

     

     

     

    CUSIP No. 73730P108Schedule 13D/APage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Matthew Halbower

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐
    (b) ☐
    3 SEC USE ONLY
    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS)

    OO

    5 Check if disclosure of legal proceedings is required pursuant to Item 2(d) or 2(e) ☐
    6 Citizenship or place of organization United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7 SOLE VOTING POWER
    0  
    8 SHARED VOTING POWER
    8,625,000  
    9 SOLE DISPOSITIVE POWER
    0  
    10 SHARED DISPOSITIVE POWER
    8,625,000  
    11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    8,625,000  
    12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
    13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 8.8%
    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    HC, IN

                   

     

     

    CUSIP No. 73730P108Schedule 13D/APage 4 of 8 Pages

     

    The following constitutes Amendment No. 2 to the Schedule 13D (“Amendment No. 2”).  This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.
     
    Item 2. Identity and Background
     
    Item 2 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:
     
    (a) This statement is filed by: (i) Pentwater Capital Management LP (the “Investment Manager”), a Delaware limited partnership, with respect to the shares of Common Stock, par value $0.0001 per share (“Common Stock”) held by certain funds (the “Pentwater Funds”) to which it serves as investment adviser and (ii) Mr. Matthew Halbower (“Mr. Halbower”), the sole shareholder of Halbower Holdings, Inc. (“Halbower Holdings”), the general partner of the Investment Manager, with respect to the shares of Common Stock held by the Pentwater Funds.
       
    (b) The address of the business office of each of the Investment Manager, Halbower Holdings and Mr. Halbower is 1001 10th Avenue South, Suite 216, Naples, FL 34102.
       
    (c) The principal business of the Investment Manager is to act as investment manager for the Pentwater Funds. The principal business of Halbower Holdings is to serve as the  general partner of the Investment Manager. Mr. Halbower’s principal occupations it to serve as the sole shareholder of Halbower Holdings.
       
    (d) During the last five years, none of the persons or entities listed above has been (convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
       
    (e) During the last five years, none of the persons or entities listed above has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
       
    (f) The Investment Manager is a Delaware limited partnership. Halbower Holdings is a Delaware corporation. Mr. Halbower is a United States citizen.
       

     

    Item 3. Source and Amount of Funds or other Consideration
     
    Item 3 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:
       
      The Reporting Persons used approximately $89,154,184, including brokerage commissions, of the working capital of the Pentwater Funds in the aggregate to purchase the shares of Common Stock reported herein as beneficially owned by the Reporting Persons.

     

    Item 4. Purpose of Transaction
       
    Item 4 of the Schedule 13D is hereby amended and supplemented to add the following:
     
      Item 6 of Amendment No. 2 is incorporated herein by reference.

     

    CUSIP No. 73730P108Schedule 13D/APage 5 of 8 Pages

      

    Item 5. Interest in Securities of the Issuer
     
    Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:
     
    (a) See rows (11) and (13) of the cover page to this Schedule 13D/A for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by each Reporting Person. The aggregate percentage of shares of Common Stock reported beneficially owned by each Reporting Person is based upon 97,466,666 shares of Common Stock outstanding as of November 22, 2024, as disclosed in the Merger Agreement (as defined in Item 6 below) attached as Exhibit 2.1 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 25, 2024.
       
    (b) See rows (7) through (10) of the cover page to this Schedule 13D for the shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) The transactions in the shares of Common Stock effected by the Reporting Persons during the past sixty (60) days, which were all in the open market, are set forth on Schedule 1 attached hereto and incorporated by reference herein.
       
    (d) No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
       
    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
       
    Item 6 of the Schedule 13D is hereby amended and supplemented to add the following:
     

    On November 25, 2024, in connection with the execution of an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Issuer, Roche Holdings, Inc., a Delaware corporation (“Parent”) and Blue Giant Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), pursuant to which, and upon the terms and subject to the conditions thereof, Merger Sub will (and Parent will cause Merger Sub to) commence a tender offer (the “Tender Offer”) no later than December 10, 2024, to acquire all of the issued and outstanding shares of Common Stock, at an offer price of (i) $9.00 per share in cash, and (ii) one non-tradeable contingent value right per share (a “CVR”), the Pentwater Funds , in each case, in their capacity as a stockholder of the Issuer, entered into a Tender and Support Agreement with the Parent (the “Pentwater Support Agreement”). Under the terms of the Pentwater Support Agreement, the Pentwater Funds have agreed, among other things, to tender their shares of Common Stock in the Tender Offer, vote their shares of Common Stock against any action that is intended or would reasonably be expected to impede or interfere with transactions contemplated by the Merger Agreement at any annual or special meeting of the stockholders of the Issuer, or in connection with any action proposed to be taken by written consent of the stockholders of the Issuer, not to transfer any of their shares of Common Stock (subject to certain exceptions), to waive and not to exercise any appraisal rights in respect of such shares of Common Stock that may arise with respect to the Merger (as defined in the Merger Agreement) and not to commence or join, and to take all actions to opt out of, any class action with respect to claims against Parent, Merger Sub, the Issuer or their affiliates relating to the Merger Agreement or the transactions contemplated thereby.  Notwithstanding the foregoing, the Parent has consented to the transfer of (i) up to 30% of the shares of Common Stock held at the time of entering into the Pentwater Support Agreement and (ii) any shares of Common Stock acquired after entering into the Pentwater Support Agreement, subject to certain conditions.

     

    CUSIP No. 73730P108Schedule 13D/APage 6 of 8 Pages

      

    The description of the Pentwater Support Agreement is qualified in its entirety by reference to the full the terms of the Tender and Support Agreement, the form of which is attached hereto as Exhibit 99.3 and incorporated herein by reference.
     
    The Pentwater Funds have entered into notional principal amount derivative agreements (the “Cash Derivative Agreements”) in the form of cash settled swaps with respect to an aggregate of 4,250,000 shares of Common Stock of the Issuer (collectively representing economic exposure comparable to 4.4% of the shares of Common Stock of the Issuer). The Cash Derivative Agreements provide the Pentwater Funds with economic results that are comparable to the economic results of ownership but do not provide them or the Investment Manager with the power to vote or direct the voting or dispose of or direct the disposition of the shares that are referenced in the Cash Derivative Agreements (such shares, the “Subject Shares”). The Investment Manager disclaims beneficial ownership in the Subject Shares. The counterparties to the Cash Derivative Agreements are unaffiliated third-party financial institutions.

     

    Item 7. Material to be Filed as Exhibits.
       
    Item 7 of the Schedule 13D is hereby amended and supplemented to add the following:
       
    Exhibit 99.2: Joint Filing Agreement.
       
    Exhibit 99.3: Form of Tender and Support Agreement (incorporated by reference to Exhibit 10.1 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 25, 2024).

     

     

     

    CUSIP No. 73730P108Schedule 13D/APage 7 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    DATED: November 27, 2024

     

    Pentwater Capital Management LP
    By: Halbower Holdings, Inc., its general partner  
       
    By: /s/ Matthew Halbower  
    Name: Matthew Halbower  
    Title: Chief Executive Officer  
       
       
    /s/ Matthew Halbower  
    Matthew Halbower  

     

     

     

     

    CUSIP No. 73730P108Schedule 13D/APage 8 of 8 Pages

    SCHEDULE 1

     

    Transactions in the Shares of Common Stock of the Issuer by the Reporting Persons During the
    Past Sixty (60) Days

     

    The following table sets forth all transactions in the shares of Common Stock reported herein effected during the past sixty (60) days by the Reporting Persons. Except as noted below, all such transactions were effected by the Reporting Persons in the open market through brokers and the price per share excludes commissions. Where a price range is provided in the column titled “Price Range ($)”, the price reported in the column titled “Price Per Share ($)” is a weighted average price. These shares of Common Stock were sold or purchased in multiple transactions at prices between the price ranges indicated in the column titled “Price Range ($)”. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the shares of Common Stock sold or purchased at each separate price.

     

    Trade Date Shares Purchased (Sold) Price Per Share ($) Price Range ($)
    11/26/2024 2,650,000 9.3002 9.21-9.46

     

     

     

     

    Get the next $PSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTX

    DatePrice TargetRatingAnalyst
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    1/4/2023$15.00Buy
    H.C. Wainwright
    1/7/2022$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Poseida Therapeutics Inc.

      SC 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      11/27/24 7:01:59 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      6/7/24 1:30:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Poseida Therapeutics Inc. (Amendment)

      SC 13G/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      5/8/24 4:01:24 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Poseida Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Poseida Therapeutics from Overweight to Neutral and set a new price target of $10.00

      12/2/24 10:07:39 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Poseida Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Poseida Therapeutics with a rating of Buy and set a new price target of $15.00

      1/4/23 7:49:53 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Poseida Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Poseida Therapeutics with a rating of Overweight and set a new price target of $24.00

      1/7/22 8:13:46 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting

      Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO, Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy

      12/9/24 12:00:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.

      Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals Division SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, auto

      11/26/24 1:10:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MaxCyte Appoints Cynthia Collins to its Board of Directors

      ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members. "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Mahe

      10/15/24 8:05:00 AM ET
      $CERT
      $MXCT
      $PSTX
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PSTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Poseida Therapeutics Inc.

      15-12G - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/21/25 6:04:42 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Poseida Therapeutics Inc.

      SCHEDULE 13D/A - Poseida Therapeutics, Inc. (0001661460) (Subject)

      1/13/25 4:05:12 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Poseida Therapeutics Inc.

      EFFECT - Poseida Therapeutics, Inc. (0001661460) (Filer)

      1/13/25 12:15:09 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Financials

    Live finance-specific insights

    See more
    • Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

      Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T

      11/7/24 4:05:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

      Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma who have previously received three or more prior lines of therapy Company to host we

      9/27/24 4:30:00 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

      Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that

      9/5/24 9:00:00 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Malin Life Sciences Holdings Ltd closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/10/25 4:10:32 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Amado Rafael closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:50 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Corning Luke closing all direct ownership in the company (SEC Form 4)

      4 - Poseida Therapeutics, Inc. (0001661460) (Issuer)

      1/8/25 2:17:02 PM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care